A new GLP-1 pill has produced greater weight loss in people with type 2 diabetes.
Researchers tested orforglipron against oral semaglutide in a year-long phase 3 study.
Patients taking orforglipron lost up to eight percent of their body weight.
Those using semaglutide lost about five percent.
The new drug also lowered average blood sugar more strongly.
More than 1,500 adults joined the trial across five countries.
Participants received different daily doses of either medication.
Orforglipron works like other GLP-1 therapies.
It reduces appetite, slows digestion, and improves glucose control.
Patients can take it without fasting, which simplifies daily use.
However, more users stopped treatment because of side effects.
Gastrointestinal problems caused most discontinuations.
Regulators have not yet approved the drug.
Experts believe effective tablets could widen access to obesity and diabetes care.
They expect future therapies to target weight, glucose, and heart risk together.
